Home Clinical Topics FDA approves new product to treat hereditary angioedema

FDA approves new product to treat hereditary angioedema

On July 16, the U.S. Food and Drug Administration (FDA) approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema.
Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here